Monogenic glucokinase diabetes and pregnancy: a case study
Language English Country Austria Media print-electronic
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Diabetes Mellitus, Type 2 diagnosis drug therapy MeSH
- Adult MeSH
- Diabetes, Gestational diagnosis drug therapy MeSH
- Hypoglycemic Agents therapeutic use MeSH
- Insulin therapeutic use MeSH
- Humans MeSH
- Pregnancy MeSH
- Pregnancy Outcome MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Hypoglycemic Agents MeSH
- Insulin MeSH
It is estimated that up to 3 % of patients with gestational diabetes have glucokinase diabetes, termed also maturity-onset diabetes of the young type 2. The disorder has autosomal dominant inheritance. There is a 50 % risk of transmission of the gene to next generation. Two scenarios with different approach to the treatment may occur in pregnancy with glucokinase diabetes: either the fetus inherits the glucokinase mutation and the treatment of maternal hyperglycemia by insulin could increase the risk of fetal growth restriction, or the fetus is without glucokinase gene mutation and untreated hyperglycemia of the mother increases the risk of macrosomia and perinatal morbidity and insulin therapy is necessary. This article describes the outcome of two pregnancies in a patient with monogenic diabetes with glucokinase deficiency. A specific approach to the treatment is discussed.
See more in PubMed
Diabetologia. 2002 Mar;45(3):427-35 PubMed
Nat Genet. 1998 Jul;19(3):268-70 PubMed
Diabetologia. 2000 Feb;43(2):250-3 PubMed
Diabetes Care. 2012 Sep;35(9):1832-4 PubMed
QJM. 2001 Aug;94(8):435-44 PubMed
Diabet Med. 2009 Jan;26(1):14-8 PubMed
Diabetes Care. 2013 Jan;36(1):e14 PubMed
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20458-63 PubMed
